Healthcare Utilization
Primary
· 60 days
Occurrence of Emergency Department, inpatient, or observation encounters after the initial encounter at accrual
| Group | Value | 95% CI |
|---|---|---|
| Control | 1080 | |
| Intervention | 920 |
Last reviewed · How we verify
NCT03207776
An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD
Completed
NA
Results posted
Last updated 22 April 2022
What this trial tests
NA trial testing Usual Care in Chronic Obstructive Pulmonary Disease in 4,832 participants. Completed in 13 August 2018.
Timeline
12 June 2017
Primary endpoint
12 February 2018
12 February 2018
13 August 2018
Quick facts
| Lead sponsor | Wake Forest University Health Sciences |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 4,832 |
| Start date | 12 June 2017 |
| Primary completion | 12 February 2018 |
| Estimated completion | 13 August 2018 |
| Sites | 8 locations across United States |
Drugs / interventions tested
- Usual Care
- COPD Clinical Pathway
Conditions studied
- Chronic Obstructive Pulmonary Disease — all drugs for Chronic Obstructive Pulmonary Disease →
Sponsor
Wake Forest University Health Sciences
Who can join
40 and older, any sex, with Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Quality, Comfort, and Care (QCC) Defined Readmission Rate
Secondary
· 30 days
Readmission to the same facility
| Group | Value | 95% CI |
|---|---|---|
| Control | 321 | |
| Intervention | 286 |
Patient-centric (Protocol Defined) Readmission Rate
Secondary
· 30 days
Readmission to any facility within Carolinas HealthCare System
| Group | Value | 95% CI |
|---|---|---|
| Control | 753 | |
| Intervention | 659 |
30-day COPD Specific, Acute Care Utilization to Any Hospital Within the System
Secondary
· 30 day
| Group | Value | 95% CI |
|---|---|---|
| Control | 240 | |
| Intervention | 179 |
Sponsor's own description
Patients who are hospitalized at select Carolinas Healthcare System (CHS) sites with Chronic Obstructive Pulmonary Disorder (COPD) acute exacerbation symptoms will be treated per the CHS COPD Clinical Pathway. Patient outcomes will be followed, including but not limited to readmission. Patients on the pathway will also have access to navigator services.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Combining Lean and Applied Research methods to improve rigor and efficiency in acute care outcomes research: A case study.
McWilliams A, Schoen M, Krull C, Bilancia J, et al · · 2019 · cited 2× · PMID 30705993 · DOI 10.1016/j.conctc.2019.100322
Verify or expand the search:
- PubMed search for NCT03207776
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Usual Care
Trials testing the same drug.
- NCT07513805 — Implementation of Routine Walking Speed Measurements in Older Veterans · NA · not yet recruiting
- NCT07225062 — Improving HIV Prevention and Substance Use Post-Sexual Assault Services · NA · not yet recruiting
- NCT07202975 — RE-SCALE: Rehabilitation Engagement and Scaled Access With eXtended Reality and Artificial Intelligence · NA · not yet recruiting
- NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
- NCT07380932 — Catheter Ablation for AF in Patients With Severe Mitral Regurgitation After Successful Transcatheter Mitral-Valve Repair · NA · not yet recruiting
Other recruiting trials for Chronic Obstructive Pulmonary Disease
Currently open trials in the same condition.
- NCT06749262 — Inclined Versus Standard Exercise for COPD Patients · NA · recruiting
- NCT07406659 — Different Inspiratory Muscle Trainings in Patients With COPD · NA · recruiting
- NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting
- NCT07418736 — A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2 · recruiting
- NCT07069829 — Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo · recruiting
Other Wake Forest University Health Sciences trials
Trials by the same sponsor.
- NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
- NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
- NCT06876896 — Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter · NA · recruiting
- NCT07227051 — Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity · NA · recruiting
- NCT07215624 — Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03207776 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wake Forest University Health Sciences
- Last refreshed: 22 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03207776.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing